EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy of Cytoreductive Surgery (CRS) + HIPEC in Gastric Cancer with Peritoneal Metastasis: Systematic Review and Meta-Analysis

Lodovica Langellotti, Claudio Fiorillo iD, Giorgio D'Annibale, Edoardo Panza, Fabio Pacelli, Sergio Alfieri, Andrea Di Giorgio iD, Francesco Santullo

Cancers · 18.05.2024 · 16 (10) · 1929

DOI: 10.3390/cancers16101929 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.05.2024. Verfasst von Lodovica Langellotti und 7 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, Catholic University of the Sacred Hearth, 00168 Rome, Italy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peritoneal carcinomatosis is one of deadliest metastatic patterns of gastric cancer, being associated with a median overall survival (OS) of 4 months. Up to now, palliative systemic chemotherapy (pSC) has been the only recommended treatment. The aim of this study is to evaluate a potential survival benefit after CRS + HIPEC compared to pSC.

Methods

A systematic review was conducted according to the PRISMA guidelines in March 2024. Manuscripts reporting patients with peritoneal carcinomatosis from gastric cancer treated with CRS + HIPEC were included. A meta-analysis was performed, comparing the survival results between the CRS + HIPEC and pSC groups, and the primary outcome was the comparison in terms of OS. We performed random-effects meta-analysis of odds ratios (ORs). We assessed heterogeneity using the Q2 statistic.

Results

Out of the 24 papers included, 1369 patients underwent CRS + HIPEC, with a median OS range of 9.8–28.2 months; and 103 patients underwent pSC, with a median OS range of 4.9–8 months. CRS + HIPEC was associated with significantly increased survival compared to palliative systemic chemotherapy (−1.8954 (95% CI: −2.5761 to −1.2146; p < 0.001).

Conclusions

CRS + HIPEC could provide survival advantages in gastric cancer peritoneal metastasis compared to pSC.

Schlagwörter

Stichwörter der Autor:innen

HIPECcytoreductive surgerygastric cancerperitoneal metastasis

Autor:innen und Institutionen

  • General Surgery Department, Catholic University of the Sacred Hearth, 00168 Rome, Italy.
  • Department of Digestive Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Hearth, 00168 Rome, Italy.
  • Department of Peritoneum and Retroperitoneum Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Hearth, 00168 Rome, Italy.

ORCID-Profile: Claudio Fiorillo, Andrea Di Giorgio

Zitieren

APA

Langellotti, L., Fiorillo, C., D'Annibale, G., Panza, E., Pacelli, F., Alfieri, S., Di Giorgio, A., & Santullo, F. (2024). Efficacy of Cytoreductive Surgery (CRS) + HIPEC in Gastric Cancer with Peritoneal Metastasis: Systematic Review and Meta-Analysis. Cancers, 16(10), 1929. https://doi.org/10.3390/cancers16101929

Vancouver

Langellotti L, Fiorillo C, D'Annibale G, Panza E, Pacelli F, Alfieri S, et al. Efficacy of Cytoreductive Surgery (CRS) + HIPEC in Gastric Cancer with Peritoneal Metastasis: Systematic Review and Meta-Analysis. Cancers. 2024;16(10):1929. doi:10.3390/cancers16101929

BibTeX
@article{Langellotti2024,
  author = {Langellotti, Lodovica and Fiorillo, Claudio and D'Annibale, Giorgio and Panza, Edoardo and Pacelli, Fabio and Alfieri, Sergio and Di Giorgio, Andrea and Santullo, Francesco},
  title = {Efficacy of Cytoreductive Surgery (CRS) + HIPEC in Gastric Cancer with Peritoneal Metastasis: Systematic Review and Meta-Analysis},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {10},
  pages = {1929},
  doi = {10.3390/cancers16101929}
}
Kostenlos starten →